These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19270263)

  • 41. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
    Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
    J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
    Danese E; Montagnana M; Johnson JA; Rettie AE; Zambon CF; Lubitz SA; Suarez-Kurtz G; Cavallari LH; Zhao L; Huang M; Nakamura Y; Mushiroda T; Kringen MK; Borgiani P; Ciccacci C; Au NT; Langaee T; Siguret V; Loriot MA; Sagreiya H; Altman RB; Shahin MH; Scott SA; Khalifa SI; Chowbay B; Suriapranata IM; Teichert M; Stricker BH; Taljaard M; Botton MR; Zhang JE; Pirmohamed M; Zhang X; Carlquist JF; Horne BD; Lee MT; Pengo V; Guidi GC; Minuz P; Fava C
    Clin Pharmacol Ther; 2012 Dec; 92(6):746-56. PubMed ID: 23132553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
    van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
    Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.
    González-Conejero R; Corral J; Roldán V; Ferrer F; Sánchez-Serrano I; Sánchez-Blanco JJ; Marín F; Vicente V
    J Thromb Haemost; 2007 Aug; 5(8):1701-6. PubMed ID: 17596133
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
    Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
    Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.
    Liang R; Wang C; Zhao H; Huang J; Hu D; Sun Y
    Thromb Res; 2012 Jul; 130(1):38-44. PubMed ID: 22192158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel associations of VKORC1 variants with higher acenocoumarol requirements.
    Anton AI; Cerezo-Manchado JJ; Padilla J; Perez-Andreu V; Corral J; Vicente V; Roldan V; Gonzalez-Conejero R
    PLoS One; 2013; 8(5):e64469. PubMed ID: 23691226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
    Carcas AJ; Borobia AM; Velasco M; Abad-Santos F; Díaz MQ; Fernández-Capitán C; Ruiz-Giménez N; Madridano O; Sillero PL;
    Trials; 2012 Dec; 13():239. PubMed ID: 23237631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
    Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
    Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study.
    Vázquez C; Orlova M; Scibona P; Ferreyro BL; Otero V; Jáuregui EG; Arbelbide J; Belloso WH
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):496-500. PubMed ID: 29916837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients.
    Sychev DA; Rozhkov AV; Ananichuk AV; Kazakov RE
    Drug Metab Pers Ther; 2017 May; 32(2):109-114. PubMed ID: 28525318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extremely low therapeutic doses of acenocoumarol in a patient with
    Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
    Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacogenetics aspects of oral anticoagulants therapy.
    Militaru FC; Vesa SC; Pop TR; Buzoianu AD
    J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.